New drug combo tested for Tough-to-Treat blood cancers
NCT ID NCT04160052
Summary
This study tested a combination of two chemotherapy drugs, venetoclax and azacitidine, for people with high-risk myelodysplastic syndromes (MDS) or related blood cancers. It aimed to find a safe dose and see if the treatment could control the disease, especially for patients whose cancer had come back or did not respond to prior therapy. The trial was for adults with a specific high-risk form of the disease and has been terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.